Why BridgeBio Pharma, Inc. (BBIO) stock moved
BridgeBio Pharma, Inc. (BBIO) shares rose 0.9% to $81.49 as of July 21, 2026, a slight gain from the prior close of $80.76. BestStocks flagged the session as a major change for BBIO. Below, we break down what changed for BBIO, why it matters for investors, how the stock reacted, and the catalysts on the calendar.
BBIO climbed 0.9% to $81.49
BBIO rose 0.9% in its latest session, moving from $80.76 to $81.49.
What it means for BridgeBio Pharma, Inc. investors
For BridgeBio Pharma, Inc. investors, the recent signals are mixed, leaving the near-term picture neutral / mixed. On the constructive side: Positive 0.9% session move; Positive price momentum. Weighing against that: BridgeBio Pharma, Inc. (BBIO) moved −2.86% from $82.66 to $80.30 on July 16, 2026; BridgeBio Pharma, Inc. (BBIO) moved -3.27% from $85.89 to $83.08 on 2026-07-13. Wall Street's consensus price target sits at $106.50, implying +30.7% upside from $81.49. Over the past 90 days analysts logged 0 upgrades and 1 downgrade. BestStocks rates the overall signal quality weak (0/100). With earnings roughly 14 days out, the next report is the most likely near-term test of the move.
BBIO price reaction
BBIO last traded at $81.49, up $0.73 (+0.91%) from the previous close of $80.76. The session traded on 0.1× average volume (below avg), so participation was unremarkable. Over the past month the stock has ranged between $68.63 and $90.17, and it currently sits about 60% of the way up that band.
Bullish and bearish analyst opinions on BridgeBio Pharma, Inc. (BBIO)
The consensus analyst price target on BridgeBio Pharma, Inc. (BBIO) is $106.50, 30.7% above the recent $81.49. Over the past 90 days analysts logged 0 upgrades, 11 maintains, and 1 downgrade. Here is how the bullish and bearish cases on BBIO line up.
The bullish case
- Wall Street's consensus price target of $106.50 implies +30.7% upside from $81.49.
- The Street's most bullish target is $157.00 (+92.7%).
- Positive 0.9% session move.
- Positive price momentum.
- BBIO moved +0.54% from $77.91 to $78.33 on 2026-07-08.
The bearish case
- 1 analyst downgrade in the past 90 days, most recently Raymond James to Market Perform (2026-05-26).
- BridgeBio Pharma, Inc. (BBIO) moved −2.86% from $82.66 to $80.30 on July 16, 2026.
Weighing both sides, BestStocks' composite read of recent signals is roughly balanced, as the bull-versus-bear meter above shows. This is an educational summary of the bull and bear case, not investment advice.
Analyst price targets and ratings are FMP consensus figures as of Jul 21, 2026; other aggregators may differ. High and low targets show the range of estimates, not forecasts.
Previous notable changes for BBIO
Frequently asked questions about BBIO
Why did BridgeBio Pharma, Inc. (BBIO) stock move?
BBIO rose 0.9% to $81.49. No single company-specific catalyst was confirmed during the move window, and it looks technical.
How much did BBIO stock rise?
BBIO gained 0.91% ($0.73) versus the prior close of $80.76, last trading at $81.49 on 0.1× average volume.
When is BridgeBio Pharma, Inc.'s next earnings date?
BBIO's next earnings report is estimated for 2026-08-04 — about 14 days away.
What is the analyst price target for BBIO?
The consensus analyst price target for BBIO is $106.50, about 30.7% above the current $81.49. Over the past 90 days, analysts recorded 0 upgrades, 11 maintains, and 1 downgrade.
How BestStocks tracks BBIO
This page is generated automatically by BestStocks' change-detection system after its price and volume cleared BBIO-specific materiality thresholds, triggering an evidence check. It draws on 12 tracked change events for BBIO, cross-checked against the data sources listed below. Price, volume, and market-capitalization figures are the live intraday quote as of July 21, 2026 and refresh as new information is detected; for companies with multiple share classes, market-cap figures can differ by data source. Analyst price targets and ratings are FMP consensus. This is an educational summary of what changed and why — not personalized investment advice.